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 The overall objective of this study is to find a method to estimate
the required ozone dose for removal of a micropolutants -
exemplified by active pharmaceutical ingredients (APIs) – in
WWTP effluents of different quality.
 The specific objective of this study was to identify the required O3




 The removal of 42 APIs by different added ozone doses were
investigated in effluents from 6 Swedish WWTP.
 A curve was fitted to the O3 dose- API removal data in order to
estimate the required O3 doses to achieve 90% degradation of each
pharmaceutical in each effluent.
 It was attempted to correlate the effective O3 doses in different
effluents with basic wastewater parameters (i.e., DOC, COD,
alkalinity)
 Rather than using the second order rate constants.
 kO3,API >104 M-1s-1, easily degraded.
 kO3,API < 104 M-1s-1, are more recalcitrant to O3
 You cannot determine the O3 doses needed (matrix effects)
(Hollender et al., 2009; Huber et al., 2003; Zimmermann et al., 2011).
Experiment and analysis
6 Effluents (secondary treatment) from WWTP  (different treatment processes , matrix 
characteristic-COD, N-NH4+, alkalinity) were spiked with an APIs mixture (45) of 
nominal concentration of 1 μg/L and treated by varying ozone doses in triplicate.
Preparation of O3 stock solution (~35mg/L O3)
Delivered O3 dose (0,5 <O3<12 mg/L) was measured with the indigo method 
(λ=600nm) in Milli-Q water. 
Bottles were placed in a waterbath at T=15oC
Quantification of APIs - Liquid chromatography-tandem mass-spectrometry (LC-
MS/MS)
Our parameter, DDO3, is the O3 dose required to achieve 90% removal of a 
micropolutant in an effluent.
The concept was based on the equation suggested by James Bolton that 
correlates EED (electrical energy dose) of energy intensive treatment 
processes with the concentration reduction of the treatment target:
where Ci and C is the initial and the final concentration, respectively, EED is the electrical 
energy dose in kWh/m³ and EEO is the electrical energy per order. 
This approach has been used before for the O3 of estrogenic compounds from WW 
(Hansen et al., 2010):
A single parameter which describes the removal 






























Bolton, J.R., et al., Pure and Applied Chemistry (2001) 73(4), 627-637.
Hansen, K.M.S. et al., Water Science and Technology 2010, 62, 649-657
Example of curve fitting to determine DDO3
kO3,API= 2,62∙104 - 2,97∙105 ( M1s-1)
kHO,API= 8,4 ∙109 ( M1s-1)
Benitez et al. Chemosphere, 2009, 77, 53-59.























Results: WW effluents characteristics
Table 1. Source and characterization of the wastewater effluents. 
WWTP Källby 1 Källby 2 Björnstorp Öresundsverket Sjölunda Nykvarnsverket 
Eff1 Eff2 Eff3 Eff4 Eff5 Eff6 
COD, mg/L 29 51 30 36 90 44 
DOC, mg/L 7.5 6.5 5.2 8.1 13.7 8.4 
Alkalinity, mg HCO3-/L  244 154 185 229 256 164 
pH 6.6 6.7 7.0 7.2 6.7 6.8 
N-NH4+, mg/L 1.36 2.98 0.77 4.93 1.86 5.98 
SUVA, (L/mg)/m  2.74 2.94 2.07 2.10 1.86 2.01 
A254, cm-1  0.206 0.190 0.107 0.171 0.256 0.168 
 
Results: Required O3 dose to degrade 45 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Results: Required O3 dose to degrade 45 
pharmaceuticals in effluents from 6 sources
Results: Concentration profiles




















































The intersect of the black horizontal line with the 10 % remaining API
concentration (y-axis) indicates the corresponding DDO3. T-bar represent
standard deviation with n=3.






























DDO3 (ppm O3) [DDO3/DOC] 
API Eff1 Eff2 Eff3 Eff4 Eff5 Eff6 Eff1 Eff2 Eff3 Eff4 Eff5 Eff6 Ave
Easily degradable 
Repaglinide  2.6 3.7 1.8 4.1 8.7 1.5 0.35 0.57 0.35 0.50 0.64 0.18 0.43 
Ezetimibe  3.2 4.6 1.5 3.8 8.0 2.0 0.43 0.71 0.29 0.47 0.58 0.24 0.45 
Diltiazem 3.6 3.7 2.2 4.3 8.0 3.9 0.48 0.57 0.42 0.53 0.58 0.47 0.51 
Eprosartan  3.2 4.9 1.9 4.5 9.1 4.2 0.43 0.76 0.37 0.55 0.66 0.50 0.55 
Trimethoprim  4.0 4.3 2.1 4.4 9.7 3.9 0.53 0.67 0.40 0.54 0.71 0.47 0.55 
Clomipramine  2.3 7.3 2.4 3.7 7.5 4.2 0.31 1.13 0.46 0.45 0.55 0.50 0.57 
Risperidone  3.5 4.7 0.9 5.5 12.1 5.0 0.47 0.73 0.17 0.68 0.88 0.60 0.59 
Hydroxyzine 3.4 5.7 1.9 4.8 10 4.8 0.45 0.88 0.37 0.59 0.73 0.57 0.60 
Codeine 4.2 4.9 2.4 4.6 9.2 5.4 0.56 0.76 0.46 0.57 0.67 0.65 0.61 
Carbamazepine 5.1 5.4 2.2 4.3 10.8 3.5 0.68 0.84 0.42 0.53 0.79 0.42 0.61 
Naproxen 5.7 5.0 2.5 6.4 10 3.7 0.76 0.77 0.48 0.79 0.73 0.44 0.66 
Fexofenadine 5.2 5.8 3.0 6.5 9.1 2.9 0.69 0.90 0.58 0.80 0.66 0.35 0.66 
Orphenadrine  4.5 5.0 3.4 4.8 12.1 4.0 0.60 0.77 0.65 0.59 0.88 0.48 0.66 
Diclofenac  4.7 5.8 NA* 3.5 10 NA* 0.63 0.90 NA* 0.43 0.73 NA* 0.67 
Cilazapril 4.5 7.1 2.7 5.7 11 4.0 0.60 1.10 0.52 0.70 0.80 0.48 0.70 
Moderately degradable 
Loperamide  2.0 4.5 <0.5 5.7 13.3 8.7 0.27 0.70 NA** 0.70 0.97 1.04 0.74 
Glimepiride 7.0 7.6 3.6 6.7 >>8.9 0.6 0.93 1.18 0.69 0.82 NA** 0.07 0.74 
Rosuvastatin 5.4 5.6 3.3 5 14.5 4.8 0.72 0.87 0.63 0.61 1.06 0.57 0.74 
Haloperidole 4.8 7.8 1.5 6.3 11.8 5.9 0.64 1.21 0.29 0.77 0.86 0.71 0.75 
Sulfamethoxazole 4.8 4.5 3.6 4.5 17.6 NA* 0.64 0.70 0.69 0.55 1.28 NA* 0.77 
Verapamil NA* 5.4 <0.5 5.0 10.5 7.5 NA* 0.84 NA** 0.61 0.77 0.90 0.78 
Tramadole  5.7 5.8 3.4 6.3 13 6.4 0.76 0.90 0.65 0.77 0.95 0.77 0.80 
Citalopram 5.0 7.8 2.0 7.1 15 5.0 0.67 1.21 0.38 0.87 1.09 0.60 0.80 
Sertraline 6.4 5.2 1.7 7.9 12 11.6 0.85 0.81 0.33 0.97 0.88 1.39 0.87 
Venlafaxine  5.3 6.3 3.4 6.4 16.6 9.3 0.71 0.98 0.65 0.79 1.21 1.11 0.91 
Maprotiline  7.3 6.9 4.1 8.3 13.6 7.2 0.97 1.07 0.79 1.02 0.99 0.86 0.95 
Bisoprolol  7.2 6.0 3.3 7.3 21 7.2 0.96 0.93 0.63 0.90 1.53 0.86 0.97 
Amitriptyline  7.3 9.4 3.6 8.3 13.6 7.3 0.97 1.46 0.69 1.02 0.99 0.87 1.00 
Metoprolol  6.9 6.9 3.8 7.4 18.2 8.8 0.92 1.07 0.73 0.91 1.33 1.05 1.00 
Biperiden  5.9 6.3 4.3 7.3 23 7.4 0.78 0.98 0.83 0.90 1.68 0.88 1.01 
Levonorgestrel  6.7 7.3 6.6 6.0 18.2 6.5 0.89 1.13 1.27 0.74 1.33 0.78 1.02 
Fluoxetine 6.6 6.8 3.1 7.7 20 11.3 0.88 1.05 0.60 0.95 1.46 1.35 1.05 
Irbesartan  8.7 7.7 5.4 11.5 13.7 4.3 1.16 1.19 1.04 1.41 1.00 0.51 1.05 
Bupropion  8.1 8.0 5.2 9.3 >>8.9 12.1 1.08 1.24 1.00 1.14 NA** 1.45 1.18 
Recalcitrant towards ozone degradation 
Oxazepam  12.3 11.3 7.1 13.5 18.4 9.7 1.64 1.75 1.37 1.66 1.34 1.16 1.49 
Ketoprofen  13.4 12.7 5.5 13.2 23.9 9.7 1.78 1.97 1.06 1.62 1.74 1.16 1.56 
Memantine 11.4 12.8 7.8 14.5 21.3 10.2 1.52 1.98 1.50 1.78 1.55 1.22 1.59 
Ibuprofen 11.5 10.9 7.3 14.7 27 10.4 1.53 1.69 1.40 1.81 1.97 1.24 1.61 
Beclomethasone  20 18 5.8 12 >>8.9 9.2 2.66 2.79 1.12 1.47 NA** 1.10 1.83 
Atracurium  3.7 6.2 4.4 11 11.1 3.9 0.49 3.13 0.85 1.35 0.81 0.47 1.18 
Flutamide >>10.2 25 11.7 17.9 >>8.9 9.4 NA** 3.87 2.25 2.20 NA** 1.12 2.36 
Fluconazole  15.1 18 10.7 20 >>8.9 22 2.01 2.79 2.06 2.46 NA** 2.63 2.39 
 
Ozone dose for removal of the first decade of 
selected pharmaceuticals in each wastewater
DDO3 (ppm O3) DDO3/DOC
Pharmaceutical Eff1 Eff2 Eff3 Eff4 Eff5 Eff6 Eff1 Eff2 Eff3 Eff4 Eff5 Eff6 Ave
Easily degradable
Carbamazepine 5.1 5.4 2.2 4.3 10.8 3.5 0.68 0.84 0.42 0.53 0.79 0.42 0.61
Naproxen 5.7 5.0 2.5 6.4 10 3.7 0.76 0.77 0.48 0.79 0.73 0.44 0.66
Diclofenac 4.7 5.8 NA 3.5 10 NA 0.63 0.90 NA 0.43 0.73 NA 0.67
Moderately degradable
Citalopram 5.0 7.8 2.0 7.1 15 5.0 0.67 1.21 0.38 0.87 1.09 0.60 0.80
Metoprolol 6.9 6.9 3.8 7.4 18.2 8.8 0.92 1.07 0.73 0.91 1.33 1.05 1.00
Fluoxetine 6.6 6.8 3.1 7.7 20 11.3 0.88 1.05 0.60 0.95 1.46 1.35 1.05
Recalcitrant towards ozone degradation
Memantine 11.4 12.8 7.8 14.5 21.3 10.2 1.52 1.98 1.50 1.78 1.55 1.22 1.59
Ibuprofen 11.5 10.9 7.3 14.7 27 10.4 1.53 1.69 1.40 1.81 1.97 1.24 1.61
Beclomethasone 20 18 5.8 12 >>8.9 9.2 2.66 2.79 1.12 1.47 NA 1.10 1.83
Required ozone doses for removing pharmaceuticals from
wastewater effluents.
Maria. G. Antoniou, Gerly Hey, Sergio Rodríguez-Vega, Aikaterini
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